Ibex Investors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Ibex Investors’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,616	Closed	-$212K	–	60
2018 Q4	$212K	Buy	+10,616	New	+$209K	0.03%	143

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ibex Investors's AMPH Position: Q1 2019 in Review

Ibex Investors sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2019, closing a stake of 10,616 shares — an estimated $212K sold.

Ibex Investors first reported a position in AMPH in Q4 2018 and held it in 1 quarter. The position peaked at $212K in Q4 2018. 135 funds tracked by Wall St. Rank hold AMPH as of Q1 2019.

Ibex Investors reported no remaining Amphastar Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Ibex Investors sold 10,616 Amphastar Pharmaceuticals shares in Q1 2019, an estimated $212K.
Ibex Investors first reported a position in Amphastar Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Ibex Investors's Amphastar Pharmaceuticals position peaked at $212K in Q4 2018.
135 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2019.

Based on Ibex Investors's 13F filing for Q1 2019, filed 7 May 2019.